Home
About Us
About Us

Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs.
News
R&D
R&D

Primarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases.
Investor Relations
Investor Relations

Guided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
Our Businesses
- NL-PHARM
- Hounland
Our Businesses

Owns Beijing Northland Biopharmaceutical Co., Ltd. and Beijing Huons Pharmaceutical Co., Ltd., which are engaged in bioengineering drugs and ophthalmic products, respectively.

Language

中文简体

English

Recombinant human thymosin β4 has received clinical trial approval.

发布时间：2015-12-24

Recently, recombinant human thymosin β4, independently developed by Beijing Northland Biotechnology Co., Ltd., has received the Phase I/II clinical trial approval from the National Medical Products Administration. The approved indication for this trial is the treatment of acute myocardial infarction. This project is classified as a Class 1 new biological drug for therapeutic use and is being reviewed under the special major project category.

2015-12

NORTHLAND’s patent wins the China Patent Excellence Award.

发布时间：2015-12-18

On December 15, 2015, the 17th China Patent Award Ceremony was held at the National Intellectual Property Administration. Our company’s invention patent, “Thymosin β4 Derivatives and Their Applications” (Patent No.: ZL200680025339.0), received the “China Patent Excellence Award” presented by the National Intellectual Property Administration. Nie Liya, Executive Deputy General Manager of the company, attended the award ceremony.

2015-12

NORTHLAND received funding for the 2015 Beijing Patent Commercialization Project.

发布时间：2015-12-16

Recently, the Beijing Intellectual Property Bureau website published the "Announcement of Review Results for 2015 Beijing Patent Commercialization Projects." NORTHLAND's "Technology Transfer of Recombinant Human Thymosin β4" was successfully selected as an outstanding patent commercialization project for 2015 and has completed the procedures for receiving the project funding.

2015-12

The concluding meeting for the Phase II clinical trial of recombinant human hepatocyte growth factor naked plasmid injection was successfully held.

发布时间：2015-12-08

On December 4, 2015, the concluding meeting for the Phase II clinical trial of recombinant human hepatocyte growth factor naked plasmid injection was successfully held at the Tai Shan Hotel in Beijing. More than ten experts from eight organizations—including the sponsor, the statistical unit, and the clinical trial institutions—attended the meeting.

2015-08

NORTHLAND Signs Technology Transfer Agreement with South Korean Company Huons

发布时间：2015-08-18

Recently, Beijing Northland Biotechnology Co., Ltd. signed an agreement with South Korea's Huons Co., Ltd. in Beijing for the technology transfer of the recombinant human thymosin β4 project. This marks another major collaboration between the two companies following their establishment of a joint venture in China in 2011.

2015-08

NORTHLAND Accepts Interview by Beijing TV

发布时间：2015-08-07

By employing precision diagnostic methods such as gene sequencing, we can identify the key underlying causes and administer targeted therapies, tailoring unique treatment plans for each patient. Precision medicine represents an important direction for future research and development, offering breakthroughs in the treatment of challenging diseases such as tumors and cancer.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

ADR information: Click to Download

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

Web site

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license